Introduction
Non-valvular atrial fibrillation (NVAF) is associated with a five-fold increased risk of ischaemic stroke. 1 However, this risk varies according to individual characteristics and associated comorbidities. Among these risk factors for ischaemic stroke, the role of female sex is still debated. Indeed, some studies found a substantial increased risk of thromboembolic events in women compared with men 2-5 whereas others found only a modest increased risk. [6] [7] [8] [9] [10] The underlying mechanism for the higher risk of ischaemic stroke in women with NVAF is unclear and several explanations have been proposed such as the higher prevalence of hypertension in women, or left atrial structural differences, among others. On the other hand, such a marginally higher risk may be, at least partly, due to residual confounding. Indeed, previous studies generally controlled for potential confounders measured at cohort entry rather than during follow-up. However, characteristics of patients may change rapidly over time, especially in older patients and this is precisely in those older patients that women were found at higher risk of stroke than men. Therefore, it is conceivable that residual confounding may account for these findings.
Our primary objective was therefore to assess whether the risk of ischaemic stroke differed between men and women in a large population-based cohort of patients with incident NVAF when suboptimal vs. optimal adjustment for covariates was used. We also examined the impact of female sex on mortality and rate of bleeding in patients with NVAF.
Methods

Source of data
This study was conducted using the computerized databases of the Régie de l'assurance maladie du Québec (RAMQ), the Maintenance et exploitation des données pour l'étude de la clientèle hospitalière (MED-ECHO), and the Institut de la statistique du Québec (ISQ), which have been described in detail elsewhere. 11 Briefly, health care coverage is mandatory for all Québec residents, and the RAMQ is responsible for administering these universal health care services and maintaining three computerized databases. The demographic database contains the age, sex, and postal code of all individuals registered. The medical services database contains information on the medical services, such as nature of the service rendered, specialty of treating and referring physician, date, and location. The prescription database contains information on outpatient prescription medications including name, dose, and amount of drug dispensed, date, prescribed number of days of treatment, and whether it was a refill or a new prescription. This program covers all individuals 65 years of age and older, welfare recipients, and all Québec residents who do not have private medication insurance or who choose to be covered by the RAMQ program. MED-ECHO maintains the hospital inpatient database which contains data pertaining to all Québec hospitalizations (including day surgery and inpatient stays). Finally, the cause of death database, administered by ISQ, contains the date, cause, and place of death. Record linkage within the RAMQ databases and with MED-ECHO is made using the individual's numéro d'assurance-maladie (health insurance number), a unique number acquired at birth or at the time of residency. The general accuracy of linkage between the prescription and the medical services databases was found to be 98.2%, and the quality of the databases has been well documented.
12,13
The study protocol was approved by the Research Ethics Committee of the Jewish General Hospital, Montreal, Canada.
Study design and cohort definition
We conducted a retrospective cohort study within the RAMQ. From the source population of all individuals in the RAMQ database, we first identified all patients, at least 18 years of age, with an inpatient or outpatient diagnosis for atrial fibrillation (ICD-9: 427.3, 427.31, 427.32; ICD-10: I48, I48.0, I48.1) between 1 January 2000 and 31 December 2009, and with RAMQ medication coverage for at least 2 years prior to cohort entry in order to provide sufficient baseline information on comorbidities and prior medication use. Cohort entry (time zero) for all patients was defined as the date of the first diagnosis of NVAF. If the diagnosis occurred during a hospitalization, cohort entry was set as the date of hospital discharge. To confirm the incident nature of the NVAF diagnosis, all patients with any mention of AF in the 2 years prior to cohort entry diagnosis were excluded. We also excluded patients with a history of valvular aortic or mitral heart disease, previous valvular repair, or hyperthyroidism (either a treatment or a diagnosis) in the 2 years prior to cohort entry, as well as patients with vitamin K antagonists (VKA) prescription in the year before cohort entry. All patients were followed until the first ischaemic stroke (or bleeding, depending on the outcome being studied), RAMQ deregistration, death, or end of the study period (31 December 2009), whichever occurred first. The occurrence of death was determined from RAMQ and ISQ. MED-ECHO was used to identify inhospital deaths.
Outcomes definition
Within the study cohort, three outcome events were identified and analysed separately, namely ischaemic stroke, bleeding, and all-cause death. Ischaemic stroke comprised transient ischaemic attack (TIA), ischaemic stroke, and systemic thromboembolic events (TE). Ischaemic events and bleeding events were defined as hospital diagnosis or as the primary cause of death in absence of a hospitalization. The date of the event was assigned the date of hospital admission or the date of death. Bleeding events were classified as either major or non-major bleeding.
Major bleeds consisted primarily of intracranial haemorrhages, hospitalized bleeds associated with a blood transfusion intervention, and any fatal bleeds. 14 Other bleeds were considered non-major bleeding events. A hospitalization presenting diagnoses for both major and non-major bleeds was classified as a major bleeding event.
Data analysis
Crude incidence rates of ischaemic stroke, death, and major bleeding, along with 95% confidence intervals (CIs) were estimated, stratified by age and sex, based on the Poisson distribution. We used two different approaches to estimate the association between female sex and each of the outcomes in multivariate analysis, standard time-fixed and more accurate time-dependent adjustment for covariates. First, Cox proportional hazards models modified for competing risks were used to estimate the hazard ratio (HR) of ischaemic stroke, bleeding, and all-cause death according to sex, adjusting for characteristics listed in Table 1 (and medications listed in Supplementary material online, Table S1 ), and for VKA use during follow-up. All variables were measured in the 2 years before cohort entry (time-fixed adjustment), and VKA, antiplatelet treatment, age, age 2 , hypertension (defined as a diagnostic or use of antihypertensive medication), diabetes (defined as a diagnostic or use of antidiabetic medication), peripheral vascular disease, chronic kidney disease, and cancer were included as time-dependent variables in all models. When studying bleeding, we also added ischaemic stroke as a time dependent variable. CHADS 2 and CHA 2 DS 2 -VASc risk scores 15, 16 were not included in multivariate models as characteristics composing the scores were entered individually in all models. Secondly, we used a nested case-control approach to analysis. 17, 18 This approach is computationally more efficient than a full cohort approach using survival analysis with time-dependent variables in the context of large cohorts with both time-varying exposures and covariates. 19, 20 This strategy allowed us to adjust for all variables listed in Table 1 (and medications listed in Supplementary material online, Table S1 ) as well as for VKA use during follow-up as time-dependent variables, measured in the year before index date. The index date for the cases was defined as the date of the first recorded outcome of interest. For each case, all controls were selected among the cohort members in the risk sets defined by the case. Controls were matched to cases on age at cohort entry (± 1 year), and date of cohort entry (± 1 year). The index date for the controls was defined as the event date for their matched case. Conditional logistic regression was used to compute odds ratios that are unbiased estimators of incidence rate ratios (RRs), with little or no loss in precision.
In supplementary analyses, we assessed whether the risk of ischaemic events differed between men and women in different subgroups, using optimal time-dependent analysis. First patients were stratified according to outpatient vs. in-hospital AF diagnostic. Then patients were stratified according to whether or not AF was diagnosed in the context of an acute event (acute coronary syndrome, stroke, or recent cardiac surgery). Finally, we stratified patients according to early use of VKA or not (within 30 days of AF diagnosis). In this analysis, time zero for cohort entry was moved to 30 days after AF diagnosis. In a sensitivity analysis, we assessed the risk of ischaemic events restricted to ischaemic stroke and TE (i.e. excluding TIA from the composite outcome).
Confidence intervals were calculated using a significance level of 5%. All statistical procedures were performed using SAS version 9.4 (SAS Institute Inc., Cary, North Carolina).
Results
The source population included 309 556 subjects with at least one atrial fibrillation diagnosis code during the period 2000-2009 ( Figure 1 ). From these, we identified 147 622 patients satisfying cohort inclusions and exclusions criteria, and having drug insurance coverage for a minimum of two years at the time of cohort entry. Table 1 and Supplementary material online, Table S1 present the baseline characteristics of the cohort. NVAF was a hospital diagnosis in 52.0% of the patients. The mean age at NVAF diagnosis was 75.5 years (standard deviation (SD) 11.4), 48.2% were males, and the mean duration of followup was 3.06 (SD 2.79) years. Women were older at NVAF diagnosis, and 63.3% had a CHADS 2 score > _2 compared with 55.7% of men. However, most comorbidities were more prevalent in men compared with women. Forty-three percent of patients initiated an oral anticoagulant during follow-up, 75% of them in the first month after NVAF diagnosis. VKA use over time was very similar between men and women overall (Supplementary material online, Figure S1 ). Figure 2 presents the incidence rates of ischaemic stroke during the 365 days following NVAF diagnosis, stratified by age and sex. A total of 11 326 patients had a diagnosis of ischaemic stroke during 427 630 person-years of follow-up, yielding an overall incidence rate of 2.6 (2.6-2.7) per 100 persons per year (see Supplementary material on line, Table S2 ). In Cox multivariate analysis, female sex was associated with a slightly higher risk of ischaemic stroke than male (HR 1.16; 95 % CI 1.11-1.21) ( Table 2 ). This modest higher risk in women resulted in one additional ischaemic event for 10 000 person-years (adjusted risk difference (RD) 0.011; CI 95% 0.002-0.020). Mortality was lower in women compared with men (HR 0.93; 95% CI 0.91-0.95). Table 3 presents the rate ratios of ischaemic stroke and mortality associated with female sex, using a nested case-control approach with all covariables included as time-dependent in the model. The rate of ischaemic events was no longer increased in women compared with men (RR 1.01; 95% CI 0.97-1.05), whatever age at NVAF diagnosis. Results were virtually unchanged when excluding TIA from the analysis (RR Finally, in stratified analyses women were not at higher risk of ischaemic stroke than men in any subgroup ( Table 4) . Mortality rate was 19% lower in women (RR 0.81; 95% CI 0.80-0.83) ( Table 4) . Current use of VKA was associated with a decreased risk of ischaemic stroke (OR 0.64; 95% CI 0.61-0.67) and death (OR 0.72; 95% CI 0.70-0.74). Crude incidence rates of major bleeds were lower in women compared with men over the 10 years following NVAF diagnosis (see Supplementary material online, Table S2 ). Similar conclusions were reached in multivariate survival analysis and nested case-control analysis with evidence of a slightly lower risk of major bleeding in women compared with men (Tables 2 and 3 ). This effect of female sex did not vary according to the timing of VKA exposure (P = 0.54 for interaction). When considering all bleeding events, major and minor, the rate was lower in women compared with men. However, when stratified by age, this decreased risk was only driven by a lower rate in women aged 75 or older. Current use of VKA was associated with an increased risk of major bleeding (OR 1.91; 95% CI 1.83-2.00).
Discussion
Using a large population-based cohort of patients newly diagnosed with NVAF, we found that women had a slightly higher risk of ischaemic stroke than men, based on survival analysis with most variables measured at cohort entry. However, when matching on age and including all other potential confounders as time-dependent variables in the nested case-control analysis, women were no longer at higher Adjusted for all variables listed in Table 1 (and medications listed in Supplementary material online, Table S1 ), and for vitamin K antagonists use, measured in the year before index date. generally found a substantially higher risk of thromboembolic events in women compared with men, with RR ranging from 1.6 to 2.6. [2] [3] [4] [5] 21, 22 Recent large observational studies reported a more modest increased risk, between 4% and 18%, [6] [7] [8] [9] and one study found no increased risk in a cohort of patients aged < 65 years. 10 Some of the previous studies were however, evaluating the predictive value of sex on the risk of stroke at the time of NVAF diagnosis rather than estimating the role of sex as a potential causal factor after NVAF diagnosis which was the objective of our study. Our finding of a 16% increased risk, based on survival analysis, is in line with previous studies. We also showed that this slight higher risk would translate in very few additional thromboembolic events in women. However, using a nested case-control approach to analysis where women and men were matched on age and all other potential confounders were timedependent, women were no longer at higher risk of ischaemic events compared with men. Results were similar in different clinical scenarios, showing that female sex was a risk factor neither in incidentally diagnosed AF nor in AF concomitant to an acute vascular event. The explanation probably mostly resides on the more accurate adjustment for age through tight matching. Indeed, women were older than men at NVAF diagnosis and heavily weighted towards the oldest categories so that the quadratic adjustment in the survival analysis was not sufficient to properly account for age differences. Also, control for potential differences in characteristics over time between men and women in the nested case-control analysis as opposed to survival analysis with most variables measured at cohort entry may play a role though to a lesser extent. Indeed, individuals being relatively old at NVAF diagnosis (cohort entry), their baseline comorbidities and drugs use are likely to change over time. Of note, exposure to anticoagulation over time was very similar between men and women and was taken into account as a time-dependent variable. Indeed, censoring patients at the time of first anticoagulation use may introduce informative censoring. Exposure to anticoagulants in previous studies varied greatly depending on the population studied and was taken into account in various ways. Our aim was to estimate the association between female sex and ischaemic stroke as a potential causal factor. In this respect, some of the covariates in our model may be intermediate variables of the effect of sex on the risk of ischaemic stroke, not confounders so that the adjustment for these factors may not be entirely appropriate. However, some characteristics may be genetically determined such as type 1 diabetes and may therefore not be considered mediators of the effect of sex. This question is debatable and would require further investigation beyond the scope of our study.
We found that women had a lower risk of bleeding overall and of major bleeding compared with men. Other studies compared the rate of bleeding in women with NVAF compared with men with inconsistent results. 2, 3, 6, 21, 23, 24 However their power was often limited, precluding any firm conclusion. Moreover, these studies estimated the rate of bleeding according to sex regardless of VKA use or adjusting for VKA use at baseline. In contrast, our estimates were based on a large cohort of patients with incident NVAF and a time-dependent measure of warfarin exposure. The differences in adherence to treatment or intensity of anticoagulation might, at least partly, explain the different bleeding rates between men and women but this information was not available in our study. In the SPORTIF trials, the quality of warfarin control was as good among women as in men but the quality of anticoagulation control might be different in daily clinical practice. 25 Overall, our findings suggest that optimal use of anticoagulation should also be encouraged in women when indicated, regardless of age. Indeed, most studies showed an underuse of anticoagulants in patients with NVAF, which was more pronounced in women. [26] [27] [28] The availability of new oral anticoagulants might improve the use and compliance to anticoagulants in the future, particularly in these undertreated subgroups of patients. Our population-based study used a large contemporary cohort of patients with incident NVAF. With up to 10 years of follow-up and a high number of events, we were able to precisely estimate the rates of major outcomes after NVAF diagnosis over time. Also, because data are prospectively collected at the time of consultation or when filling a prescription at the pharmacy, the possibility of recall bias was eliminated. Moreover, when contrasting the rates of various outcomes in men and women, we performed several analyses using time-dependent adjustment for many covariates and exposure to antithrombotic agents to minimize potential residual confounding. However, some vascular risk factors such as smoking and obesity are not routinely collected in large healthcare administrative databases such as the RAMQ and were not controlled for in our study. That being said, it is unlikely that additional adjustment for these two variables would have a major impact on our estimates since we already controlled for more than 20 potential confounders and matched on age, the strongest confounder in the nested case-control analysis. Also, we did not have information on the International normalized ratio (INR) therapeutic range for patients exposed to VKA, and we were not able to assess potential differences in the quality of anticoagulation between men and women. Another limitation is that ischaemic strokes were defined using specific diagnostic codes as well as a diagnostic code of 'stroke' with no mention of the subtype. Therefore, it is possible that some haemorrhagic strokes were misclassified as being ischaemic in our study. However, this potential bias is likely to have been minimal as around 85% of strokes are of ischaemic origin and our rates were very similar to those reported in previous studies. Moreover, restricting our definition of ischaemic stroke to events based solely on specific diagnostic codes would have greatly underestimated rates since stroke subtypes are often not mentioned in administrative databases. Finally, we did not estimate the association between sex and ischaemic stroke stratified by CHA 2 DS 2 -VASc score which could also have been informative. We chose instead to adjust for the components of the score during follow-up. In summary, in our cohort of patients with incident NVAF, women were not at increased risk of thromboembolic events compared with men when properly adjusting for age and properly accounting for changing characteristics of patients over time. Mortality rates were lower in women compared with men at any age, whereas the risk of bleeding was also slightly lower in women.
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